The Hantavirus Scare Brought 3 Covid-Era Stocks Back in the Spotlight
A hantavirus scare has revived interest in three COVID-era stocks: Moderna, Emergent BioSolutions, and BioNTech, with each showing unique chart patterns and catalysts.Summary
A hantavirus outbreak initially boosted Moderna's stock by 36% due to its mRNA platform, a collaboration on a hantavirus vaccine, and positive flu vaccine data. The stock is now consolidating in a cup-and-handle pattern, with a breakout potentially leading to significant gains.
Emergent BioSolutions, which manufactured the Johnson & Johnson COVID-19 vaccine, has seen its stock decline due to past scandals and weaker sales. However, it is forming an inverse head-and-shoulders pattern, suggesting a potential rebound if key support levels hold.
BioNTech, a co-developer of the Pfizer-BioNTech COVID-19 vaccine, is exhibiting a head-and-shoulders pattern with bullish divergence in its Chaikin Money Flow and high put-call ratios, indicating potential for a short squeeze and a reversal from its current bearish trend if it breaks above key resistance.
(Source：BeInCrypto)